Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Dorian Schönfeld

Uwe Gritzan

Julian Marius Glück

Simon Holton

Christoph Freiberg

Ernst Weber

Frank Dittmer

Sven Golfier

Jörg Willuda

Jessica Pinkert

Yingzi Ge

Philip Beckhove

Eva-Maria Gutierrez

Ingo Flamme

Mark Trautwein

Karoline Dröbner

Katharina Filarsky

Philipp Ellinger

Winfried Wunderlich

Antje Schmidt

Yalda Sedaghat

Kenneth Young

Fionnuala Mary Mcaleese Eser

Hans-Georg Lerchen

Anne-Sophie Rebstock

Beatrix Stelte-Ludwig

Yolanda Cancho Grande

Simone Greven

Lisa Dietz

Christoph Mahlert

Sven Wittrock

Sandra Berndt

Christian Votsmeier

Stephan Märsch

Nikolaus Pawlowski

Stefanie Hammer

Patrick Jones

Jenny Fitting

Gutierrez Eva-Maria

The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Semaphorin 3A (Sema3A). An antibody conjugate and a pharmaceutical composition each comprising the isolated antibody or antigen-binding fragment thereof that binds to human Sema3A are also provided.

Anti-semaphorin 3A antibodies

The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.

Anti-sema3a antibodies and uses thereof

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human andCEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-CEACAM6 antibodies and uses thereof

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

Growing community of inventors

Cologne, Germany

Dorian Schönfeld